Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ralph, Arlinghaus"'
Autor:
Pier Giuseppe Pelicci, Ralph Arlinghaus, Geraldine Mbamalu, Jiaxin Liu, Lorri Puil, Gerald D. Gish, Tony Pawson, David D.L. Bowtell
Publikováno v:
The EMBO Journal. 13:764-773
The cytosolic 185 and 210 kDa Bcr-Abl protein tyrosine kinases play important roles in the development of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL). p185 and p210 Bcr-Abl cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c57b15ac3b60fbd25e4fbc8626de1a
https://doi.org/10.1002/j.1460-2075.1994.tb06319.x
https://doi.org/10.1002/j.1460-2075.1994.tb06319.x
Autor:
Ana M, Tari, Yolanda, Gutiérrez-Puente, Giuseppe, Monaco, Clifton, Stephens, Tong, Sun, Michael, Rosenblum, John, Belmont, Ralph, Arlinghaus, Gabriel, Lopez-Berestein
Publikováno v:
International journal of oncology. 31(5)
We previously demonstrated that liposome-incorporated antisense oligodeoxynucleotide specific for the grb2 mRNA (L-Grb2) inhibited Grb2 protein expression and the proliferation of bcr-abl-positive leukemia cell lines. To determine whether L-Grb2 has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0435e9800051c38f9b1041be341fe25b
https://pubmed.ncbi.nlm.nih.gov/17912453
https://pubmed.ncbi.nlm.nih.gov/17912453
Autor:
Ralph, Arlinghaus, Tong, Sun
Publikováno v:
Cancer treatment and research. 119
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b251e56837230c0dee55ece01dabbce1
https://pubmed.ncbi.nlm.nih.gov/15164881
https://pubmed.ncbi.nlm.nih.gov/15164881
Autor:
Nicholas J, Donato, Ji Y, Wu, Jonathan, Stapley, Hui, Lin, Ralph, Arlinghaus, Bharat B, Aggarwal, Shishir, Shishodia, Maher, Albitar, Kimberly, Hayes, Hagop, Kantarjian, Moshe, Talpaz, Shishir, Shishodin
Publikováno v:
Cancer research. 64(2)
Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f58bbddac3adf3861e1538ac33903e12
https://pubmed.ncbi.nlm.nih.gov/14744784
https://pubmed.ncbi.nlm.nih.gov/14744784
Autor:
Hagop M, Kantarjian, Susan, O'Brien, Jorge E, Cortes, Sergio A, Giralt, Mary Beth, Rios, Jianqin, Shan, Francis J, Giles, Deborah A, Thomas, Stefan, Faderl, Marcos, De Lima, Guillermo, Garcia-Manero, Richard, Champlin, Ralph, Arlinghaus, Moshe, Talpaz
Publikováno v:
Blood. 100(5)
Twenty-eight adults with chronic myelogenous leukemia (CML) that had relapsed after allogeneic stem cell transplantation (SCT) received imatinib mesylate (400-1000 mg/d). Disease was in chronic phase in 5 patients, accelerated in 15, and blastic in 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cd3cf9509ceda20086fce41fcbda483e
https://pubmed.ncbi.nlm.nih.gov/12529295
https://pubmed.ncbi.nlm.nih.gov/12529295
Autor:
Kantarjian, Hagop M., Moshe Talpaz, Jorge Cortes, Brien, Susan O., Stefan Faderl, Deborah Thomas, Francis Giles, Mary Beth Rios, Jianqin Shan, Ralph Arlinghaus
Publikováno v:
Scopus-Elsevier
Augusta University-Pure
Augusta University-Pure
The purpose of our investigation was to evaluate the response and minimal residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic myeloid leukemia (CML) treated with imatinib mesylate.One hundred eighty patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4939fb7675cd3c67b4b8b5744302e1bc
http://www.scopus.com/inward/record.url?eid=2-s2.0-0346756405&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0346756405&partnerID=MN8TOARS
